Advertisement
Renowned breast cancer researcher and editor to lead department
Jame Abraham, MD, FACP, is the new Chair of Hematology/Medical Oncology at Cleveland Clinic.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In his new position, Dr. Abraham will recruit and develop staff, and guide the department’s focus on patient access and multidisciplinary care. He also will continue as Professor of Medicine at Cleveland Clinic Lerner College of Medicine.
Most recently, Dr. Abraham was Director of the Breast Oncology Program at Cleveland Clinic’s Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program.
“Successfully leading our Hematology/Medical Oncology Department requires a leader who excels at empathy, fosters a culture of teamwork, demonstrates emotional intelligence and believes in the vision of our institute,” says Brian Bolwell, MD, Chairman, Taussig Cancer Institute, Cleveland Clinic Cancer Center. “Dr. Abraham represents these qualities and has exhibited a passion for department and caregiver development, and elevating our national reputation.”
Dr. Abraham earned his medical degree from Calicut Medical College in Kerala, India. He then completed a residency at the University of Connecticut, followed by a fellowship in hematology at the National Heart, Lung, and Blood Institute and a fellowship in medical oncology at the National Cancer Institute.
He worked as Chief of Hematology/Oncology, Professor of Medicine and Bonnie Wells Wilson Distinguished Professor of Breast Cancer Research at West Virginia University before joining Cleveland Clinic in 2013.
A national principal investigator of multiple breast cancer clinical trials, Dr. Abraham has published and presented more than 200 papers. He also is Founding Editor of The Bethesda Handbook of Clinical Oncology.
Advertisement
His national breast cancer committee and leadership activities include serving as:
“I look forward to building upon Cleveland Clinic Taussig Cancer Institute’s position as a leader in hematology and medical oncology, delivering outstanding, compassionate patient care and innovative research,” says Dr. Abraham. “I am honored to serve patients who choose Cleveland Clinic for advanced cancer treatment and to support the department’s committed and passionate caregivers.”
Advertisement
Advertisement
Higher type 2 immunity observed in persistent CAR T cells
Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children
Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers
Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations